The Ethical and Technological Implications of Cloning and Genetic Manipulation

Few scientific developments have stirred as much philosophical debate as cloning and genetic manipulation. These technologies sit at the intersection of medicine, ethics, and human identity – raising questions that no laboratory can answer alone. Can science rewrite what it means to be human? And if it can, should it? To engage with these questions seriously, we first need to understand what these technologies actually do, and then confront the profound ethical terrain they open up.

The science in plain terms: what cloning and genetic manipulation actually are 🔗

Cloning, at its core, is the creation of a genetically identical copy of an organism or cell. The technique most central to the ethical debate is somatic cell nuclear transfer (SCNT) – a process in which the nucleus of a body cell is extracted and inserted into an egg cell that has had its own nucleus removed. The resulting cell is then stimulated to divide and develop. This is how Dolly the sheep, the first mammal cloned from an adult somatic cell, was produced in 1997.

There are two fundamentally different applications of this method, and conflating them is a common source of confusion in public debate. Reproductive cloning involves allowing the cloned embryo to develop into a full organism – a living being. Therapeutic cloning, by contrast, is not aimed at creating a living individual at all. Instead, the embryo is used as a source of pluripotent embryonic stem cells – cells capable of developing into virtually any tissue type in the body – for medical research and treatment. This distinction matters enormously, because the ethical concerns surrounding each are quite different.

Genetic manipulation refers to the deliberate alteration of an organism’s DNA. Today, the dominant tool for this is CRISPR-Cas9, a gene-editing technology that can cut, remove, or replace specific sequences of DNA with far greater precision and lower cost than any previous method. As researchers at the University of Virginia have noted, the ability of CRISPR to edit diverse genome types with unprecedented ease has caused considerable excitement – and alarm – across the global biomedical community.

The medical promise: organ replacement and regenerative medicine 🔗

The most compelling case for therapeutic cloning lies in what it could mean for millions of people waiting for organ transplants. According to research published in ScienceDirect, over 6,000 patients in the United States alone were reported to have died while awaiting a donor organ in 2001 – a figure that has only grown as populations age and organ shortages worsen.

Therapeutic cloning offers a potential solution to two of transplantation medicine’s most intractable problems: organ shortage and immune rejection. Because the stem cells derived from SCNT share the genetic material of the patient, tissues grown from them are far less likely to be rejected by the immune system. As a review in PMC explains, therapeutic cloning could allow the synthesis of organs suited precisely to the patient, potentially eliminating the need for immunosuppressive drugs that carry their own serious risks.

The potential medical applications are wide-ranging. The Mayo Clinic describes stem cell therapies – the direct beneficiary of therapeutic cloning research – as showing promise for conditions including Parkinson’s disease, type 1 diabetes, amyotrophic lateral sclerosis (ALS), heart failure, leukemia, and spinal cord injuries. Early animal studies have shown that stem cells derived from cloned embryos can, for example, be differentiated into dopaminergic neurons – the cells whose degeneration causes Parkinson’s – with normal electrophysiological properties.

A promising alternative: induced pluripotent stem cells 🔗

It is worth noting that the scientific landscape has shifted since therapeutic cloning first generated excitement. The Stanford Encyclopedia of Philosophy highlights that induced pluripotent stem cells (iPSCs) – body cells that are genetically reprogrammed to behave like embryonic stem cells – have raised the possibility that cloning research may be unnecessary for some therapeutic goals. iPSC research could provide patient-specific cells without relying on the creation and destruction of human embryos, sidestepping some of the most contentious ethical objections to therapeutic cloning. Whether iPSCs can fully replace SCNT-derived stem cells for all applications remains an active area of scientific investigation.

The ethical landscape: where agreement breaks down 🔗

It is in the ethical domain that the debate around cloning and genetic manipulation becomes most philosophically rich – and most contested. The concerns are not monolithic; they differ significantly depending on whether we are discussing therapeutic or reproductive cloning, and whether genetic manipulation is aimed at treating disease or enhancing traits.

The moral status of the embryo 🔗

The most foundational ethical objection to both therapeutic cloning and certain forms of genetic research concerns the status of the human embryo. As philosopher Michael Sandel has argued in a Harvard discussion paper, in order to assess the moral permissibility of cloning for stem cell research, we must first settle the question of whether the early embryo is morally equivalent to a person. If it is, then harvesting stem cells from it – even to treat devastating diseases – is morally impermissible. If it is not, the ethical calculus changes substantially. This remains one of bioethics’ genuinely unresolved questions, and it sits at the heart of why therapeutic cloning legislation varies so dramatically between countries.

Reproductive cloning and the question of identity 🔗

Human reproductive cloning – producing a living person who is genetically identical to another – raises a distinct and philosophically serious set of concerns. The Stanford Encyclopedia of Philosophy notes that some philosophers fear cloning threatens the identity and individuality of the clone, potentially violating what Joel Feinberg called the child’s “right to an open future” – the right to a life not predetermined by the existence of a genetic predecessor. The US President’s Council on Bioethics articulated this concern by arguing that genetic uniqueness is an emblem of the kind of independence that allows individuals to face an indeterminate future on their own terms.

However, this concern has also been criticized. Research published in the Journal of Medical Ethics argues that there is no evidence to show that people conceived through cloning would inevitably be unable to assume full responsibility for their own actions. Crucially, as a study in PNAS underscores, it may be possible to clone a person’s genes, but the individual cannot be cloned – character, personality, and the features that constitute a person go well beyond genotype. Identical twins, after all, share DNA and yet are clearly distinct persons with their own identities.

Still, the American Medical Association has concluded that reproductive cloning is not endorsed by the medical profession, citing the high likelihood of physical harm, the psychosocial risks to any cloned child, and the potential for reproductive cloning to be used in a eugenic or discriminatory fashion – practices explicitly incompatible with the ethical norms of medicine.

Genetic manipulation, enhancement, and the threat to diversity 🔗

The ethics of genetic manipulation – particularly through CRISPR – introduces a further dimension: the slippage between therapy and enhancement. Most people are comfortable with the idea of editing genes to eliminate a lethal inherited disease. But as the Innovative Genomics Institute points out, the same technology could be used not just to eliminate Huntington’s disease, but to reduce the risk of common conditions, or to select for traits like height, intelligence, or appearance – the so-called “designer baby” scenario.

This raises a concern that goes beyond individual choice into something with population-level consequences. Research published in Frontiers in Genome Editing warns that cultural preferences for certain physical features or abilities could, through widespread genetic selection, result in a significant loss of genetic variability – and that from an evolutionary standpoint, reduced genetic diversity means reduced capacity to adapt to environmental change and disease. What benefits individuals in the short term could harm the species in the long run.

There is also a justice dimension. Writing in The Humanist, commentators have highlighted the risk of a “genetic divide” – a world in which wealthy individuals and nations access gene therapies and enhancements that remain unavailable to the poor. The Innovative Genomics Institute notes that if germline editing remains available only to the affluent, existing socioeconomic disparities could be massively intensified – and, crucially, passed down at the genetic level to future generations. This concern connects directly to bioconservative philosophical warnings, such as those articulated by philosopher Hans Jonas, who described biotechnological interventions of this kind as intrusions into the integrity of what it means to be human – trespasses into a domain that secular ethics had treated as a boundary between human dignity and unchecked technological progress.

What international governance says 🔗

The global response to these technologies has been fragmented, reflecting genuine philosophical disagreement between nations and cultures. Britannica notes that in 2005, the United Nations passed a non-binding Declaration on Human Cloning, calling on member states to prohibit forms of human cloning incompatible with human dignity – while leaving room for countries to pursue therapeutic cloning. The UK, through its Human Fertilisation and Embryology Authority, issues licenses for creating human embryonic stem cells through nuclear transfer, strictly for legitimate therapeutic and research purposes.

On genetic manipulation, the UNESCO Universal Declaration on the Human Genome and Human Rights states that the human genome underlies the fundamental unity and dignity of all members of the human family, and that it is, in a symbolic sense, the heritage of humanity – a framing that critics of heritable genetic modification have used to argue that germline editing threatens human rights and equality. In 2018, Chinese researcher He Jiankui’s announcement that he had used CRISPR to edit the germlines of twin embryos sent shockwaves through the international scientific community – demonstrating that the governance question is not merely theoretical.

Therapy versus manipulation: where should the line be? 🔗

Perhaps the most practically urgent philosophical question is this: where does therapeutic intervention end and manipulation begin? The AMA’s Code of Medical Ethics takes the position that genetic manipulation should be reserved for therapeutic purposes, and that efforts to enhance “desirable” traits are contrary to the ethical tradition of medicine. This is a defensible principle, but the line between disease treatment and enhancement is not always clear. Is correcting a gene associated with below-average intelligence a treatment or an enhancement? Is selecting against deafness a medical decision or a statement about the worth of Deaf culture?

As Scientific American has argued, bad genes do not necessarily lead to bad lives, and good genes do not guarantee good ones. If genetic technologies are used to eliminate rather than to treat genetic difference, society risks instrumentalizing the reductionist assumption that human worth is a function of genetic makeup – an assumption with a troubling historical precedent in eugenics.

What do you think? If therapeutic cloning were proven safe and effective, should the creation and use of embryos for medical research be considered ethically acceptable given the lives it could save – or does the moral status of the embryo place an absolute limit on what medicine may do? And as genetic manipulation becomes more precise and affordable, who should have the authority to decide where the boundary between treating disease and enhancing human traits is drawn – scientists, governments, or the people most affected?

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2323472/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6286228/
3. https://www.sciencedirect.com/science/article/abs/pii/S0966327403001023
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC539246/
5. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117
6. https://plato.stanford.edu/entries/cloning/
7. https://scholar.harvard.edu/files/sandel/files/ethical_implications_of_human_cloning.pdf
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2598241/
9. https://www.pnas.org/doi/10.1073/pnas.1501798112
10. https://code-medical-ethics.ama-assn.org/ethics-opinions/cloning-reproduction
11. https://innovativegenomics.org/crisprpedia/crispr-ethics/
12. https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2025.1593172/full
13. https://thehumanist.com/commentary/the-ethics-of-gene-editing-navigating-humanist-values-in-biotechnology/
14. https://journalofethics.ama-assn.org/article/genome-editing-ethics-and-politics/2019-12
15. https://www.britannica.com/science/cloning/Ethical-controversy
16. https://www.nature.com/articles/s41599-022-01147-y
17. https://www.scientificamerican.com/article/the-dark-side-of-crispr/